Navigation Links
Gladstone scientist Deepak Srivastava named fellow of the AAAS
Date:12/16/2011

SAN FRANCISCO, CADecember 16, 2011The American Association for the Advancement of Science (AAAS) has named Gladstone Senior Investigator Deepak Srivastava, MD, a Fellow for his efforts to advance science and its applications.

Dr. Srivastava directs cardiac and stem cell research at Gladstone, an independent and nonprofit biomedical-research organization whose primary research efforts are focused in the areas of cardiovascular disease, virology and neurological disease. AAAS, which will honor all newly elected Fellows on February 18 during the 2012 AAAS Annual Meeting in Vancouver, B.C., Canada, elected Dr. Srivastava in recognition of his distinguished contributions and advancements in the fields of congenital heart disease, cardiac development and stem cell biology.

"I am honored by this recognition from my peers, and humbled to be among such an esteemed group of scientists," said Dr. Srivastava, who is also a professor of pediatrics, biochemistry and biophysics at the University of California, San Francisco (UCSF), with which Gladstone is affiliated.

Dr. Srivastava joins five other Gladstone scientists who are already AAAS Fellows: President R. Sanders Williams, MD; President Emeritus and Senior Investigator Robert Mahley, MD, PhD; Senior Investigator Warner Greene, MD, PhD, who directs Gladstone's virology and immunology research; and Senior Investigator Eric Verdin, MD, who is the associate director for virology and immunology research.

Dr. Srivastava's studies focus on applying modern genetic and stem cell technologies to identify the causes of human heart disease. His laboratory studies the molecular events regulating early and late developmental decisions that instruct progenitor cells to become cardiac cellsand subsequently fashion a functioning heart.

Drawing on his expertise in developmental biology, Dr. Srivastava and his lab have reprogrammed connective tissue in the heart directly into beating heart cellsa process that may help regenerate damaged heart muscle. Understanding the causes of heart disease and applying knowledge of these cardiac development pathways may be useful in preventing congenital defects and devising new therapies to treat acquired heart disease, particularly with cardiac-specific differentiation of embryonic stem cells. Congenital heart disease affects nearly 1 out of every 100 babies born worldwide and is the most common cause of death from a birth defect.

"We are delighted and gratified that the AAAS has recognized Deepak's achievements in the field of cardiovascular research," said Dr. Williams. "We are optimistic that his research will contribute to finding solutions to help the millions who suffer from heart disease."

Before joining Gladstone in 2005, Dr. Srivastava was a professor in the department of pediatrics and molecular biology at the University of Texas Southwestern (UTSW) Medical Center in Dallas. He has received numerous honors and awards, including endowed chairs at UTSW and UCSF, as well as election to the American Society for Clinical Investigation, the Society for Pediatric Research, and the American Academy of Arts and Sciences.


'/>"/>

Contact: Anne Holden
anne.holden@gladstone.ucsf.edu
415-734-2534
Gladstone Institutes
Source:Eurekalert

Related biology news :

1. Gladstone scientist receives American Heart Associations Katz prize for cardiovascular research
2. Gladstone founder receives American Heart Association Distinguished Scientist Award
3. Gladstone scientists identify protein form linked to Huntingtons disease
4. Gladstone scientist finds new target for treating symptoms of Parkinsons disease
5. Gladstone scientists offer new insight into the regulation of stem cells and cancer cells
6. Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS
7. Gladstone scientists identify genes involved in embryonic heart development
8. Gladstone scientists uncover mechanism for the major genetic risk factor of Alzheimers disease
9. Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
10. Gladstones Shinya Yamanaka wins Kyoto prize
11. Gladstone and Institute for Systems Biology collaborate on Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: